Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
US |
|
AngloGold Ashanti Ltd
NYSE:AU
|
ZA |
|
L
|
LG Chem Ltd
KRX:051915
|
KR |
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals makes prescription medicines, mostly biologic drugs that are built from antibodies and other protein-based therapies. It develops treatments for eye diseases, allergies, inflammation, cancer, and rare genetic disorders, then sells them through hospitals, clinics, pharmacies, and specialty distributors. Its main customers are patients and the doctors and health systems that treat them, along with insurers and government health programs that pay for the drugs. The company earns money in two main ways: by selling its own approved medicines and by sharing revenue from partnerships with larger drug companies. In some cases, it also receives licensing fees or royalties tied to drugs it helped discover or develop. That mix matters because Regeneron does not rely only on selling pills through a broad consumer market; it focuses on a smaller set of high-value biologic therapies that are usually prescribed for serious medical conditions. What makes Regeneron stand out is its deep in-house drug discovery work, especially its ability to find and design antibody medicines, and then move them through development and manufacturing. It acts both as a drug inventor and as a commercial medicine maker, which gives it more control over which products reach the market and how they are supported. In the pharmaceutical value chain, Regeneron sits near the front end, where new therapies are created, tested, and turned into branded specialty medicines.
Regeneron Pharmaceuticals makes prescription medicines, mostly biologic drugs that are built from antibodies and other protein-based therapies. It develops treatments for eye diseases, allergies, inflammation, cancer, and rare genetic disorders, then sells them through hospitals, clinics, pharmacies, and specialty distributors. Its main customers are patients and the doctors and health systems that treat them, along with insurers and government health programs that pay for the drugs.
The company earns money in two main ways: by selling its own approved medicines and by sharing revenue from partnerships with larger drug companies. In some cases, it also receives licensing fees or royalties tied to drugs it helped discover or develop. That mix matters because Regeneron does not rely only on selling pills through a broad consumer market; it focuses on a smaller set of high-value biologic therapies that are usually prescribed for serious medical conditions.
What makes Regeneron stand out is its deep in-house drug discovery work, especially its ability to find and design antibody medicines, and then move them through development and manufacturing. It acts both as a drug inventor and as a commercial medicine maker, which gives it more control over which products reach the market and how they are supported. In the pharmaceutical value chain, Regeneron sits near the front end, where new therapies are created, tested, and turned into branded specialty medicines.
Strong start: Regeneron said first-quarter 2026 revenue rose 19% year over year to $3.6 billion, while diluted net income per share increased 15% to $9.47.
Dupixent momentum: Dupixent global net sales grew 31% on a constant currency basis to $4.9 billion, with management pointing to broad demand across many indications and geographies.
EYLEA HD gains: EYLEA HD U.S. sales rose 52% to $468 million, supported by stronger physician adoption and recent label expansion, while the EYLEA franchise continues to shift toward HD.
Pipeline progress: The company highlighted positive late-stage data and upcoming FDA decisions for cemdisiran in generalized myasthenia gravis, garetosmab in FOP, and the EYLEA HD pre-filled syringe.
Manufacturing issue: GAAP gross margin was hurt by a temporary interruption at the Limerick, Ireland bulk manufacturing site, but Regeneron said product availability was not affected and full production should resume by the end of the second quarter.
Capital return: The board authorized a new $3 billion share repurchase program, and Regeneron ended the quarter with $15.8 billion in cash and marketable securities less debt.
Pricing deal: Management highlighted a Most-Favored-Nation pricing agreement with the U.S. government as part of its effort to lower drug prices while preserving innovation.
Management
Dr. Leonard S. Schleifer, M.D., Ph.D., is the founder and longtime leader of Regeneron Pharmaceuticals, Inc., a biotechnology company dedicated to developing innovative medicines for serious diseases. Born in Queens, New York, he earned both his medical degree and Ph.D. in pharmacology from the University of Virginia. Dr. Schleifer launched Regeneron in 1988, driven by a passion for science and a commitment to address unmet medical needs. Under his leadership, Regeneron has grown from a small startup into a major player in the biotech industry, known for its development of groundbreaking therapies. Notably, Regeneron developed the first approved treatment for wet age-related macular degeneration and several other successful drugs across a range of therapeutic areas, including ophthalmology, oncology, and immunology. Dr. Schleifer is known for fostering a culture of scientific innovation that emphasizes rigorous research and development as the driving force behind the company's success. His tenure at Regeneron is marked by significant achievements in both drug discovery and corporate growth, earning him recognition as one of the industry's leading executives. In addition to his work at Regeneron, Dr. Schleifer has been involved in numerous industry and academic boards, contributing to the broader scientific and medical communities. His leadership and vision have been pivotal in positioning Regeneron as a leader in biopharmaceutical innovation.
Under his leadership, Regeneron has grown from a small startup into a major player in the biotech industry, known for its development of groundbreaking therapies. Notably, Regeneron developed the first approved treatment for wet age-related macular degeneration and several other successful drugs across a range of therapeutic areas, including ophthalmology, oncology, and immunology.
Dr. Schleifer is known for fostering a culture of scientific innovation that emphasizes rigorous research and development as the driving force behind the company's success. His tenure at Regeneron is marked by significant achievements in both drug discovery and corporate growth, earning him recognition as one of the industry's leading executives.
In addition to his work at Regeneron, Dr. Schleifer has been involved in numerous industry and academic boards, contributing to the broader scientific and medical communities. His leadership and vision have been pivotal in positioning Regeneron as a leader in biopharmaceutical innovation.
Dr. George D. Yancopoulos, M.D., Ph.D., is a prominent figure in the biotechnology industry, known for his integral role in the scientific leadership of Regeneron Pharmaceuticals, Inc. As the co-founder, President, and Chief Scientific Officer of the company, he has been instrumental in pioneering numerous scientific and therapeutic innovations. He completed his undergraduate studies in biochemistry and molecular biophysics at Columbia College and earned both his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos joined Regeneron in 1989 as its founding scientist and has since been a driving force in its growth and success. His leadership and vision have led to the development of key technologies and groundbreaking medications, including treatments for eye diseases, inflammatory conditions, cancer, and infectious diseases. Notably, he played a significant role in the invention of the groundbreaking VelociSuite® technologies, including VelocImmune®, which have been fundamental in developing several successful antibody therapies. Under his scientific direction, Regeneron has consistently been at the forefront of innovation in biotechnology and pharmaceuticals. Dr. Yancopoulos' work has earned him numerous accolades, and he is widely regarded as one of the most influential scientists in the industry. His contributions extend beyond his work at Regeneron, as he continues to be actively involved in advancing scientific research and mentoring the next generation of scientists.
Dr. Yancopoulos joined Regeneron in 1989 as its founding scientist and has since been a driving force in its growth and success. His leadership and vision have led to the development of key technologies and groundbreaking medications, including treatments for eye diseases, inflammatory conditions, cancer, and infectious diseases. Notably, he played a significant role in the invention of the groundbreaking VelociSuite® technologies, including VelocImmune®, which have been fundamental in developing several successful antibody therapies.
Under his scientific direction, Regeneron has consistently been at the forefront of innovation in biotechnology and pharmaceuticals. Dr. Yancopoulos' work has earned him numerous accolades, and he is widely regarded as one of the most influential scientists in the industry. His contributions extend beyond his work at Regeneron, as he continues to be actively involved in advancing scientific research and mentoring the next generation of scientists.
Dr. Andrew J. Murphy, Ph.D., is an esteemed scientist and executive with extensive experience in biomedical research and pharmaceutical development. He currently holds the position of Senior Vice President at Regeneron Pharmaceuticals Inc., a leading biotechnology company known for its work in developing a variety of therapeutics across numerous disease areas. Dr. Murphy's career at Regeneron has been marked by his significant contributions to the company's R&D efforts, particularly in the field of genetics and genomics. He is highly regarded for his work in understanding the genetic basis of disease and for driving innovative research programs that aim to translate genetic discoveries into new therapeutic strategies. His expertise has been instrumental in advancing Regeneron's pipeline of investigational drugs and therapeutic products. In addition to his role at Regeneron, Dr. Murphy is also recognized for his academic contributions. He holds a Ph.D. in a relevant scientific field and has been involved in numerous publications and presentations that outline advancements in genetic research and biotechnology. His leadership extends beyond his scientific acumen, as he plays a pivotal role in fostering collaborations with academic institutions, industry partners, and regulatory bodies to enhance the development and delivery of novel therapies. Dr. Murphy's work continues to contribute significantly to Regeneron's mission of delivering innovative medicines to patients with unmet medical needs. His dedication to science and medicine exemplifies the impact of leadership in driving forward the boundaries of what is possible in biopharmaceutical research and development.
Dr. Murphy's career at Regeneron has been marked by his significant contributions to the company's R&D efforts, particularly in the field of genetics and genomics. He is highly regarded for his work in understanding the genetic basis of disease and for driving innovative research programs that aim to translate genetic discoveries into new therapeutic strategies. His expertise has been instrumental in advancing Regeneron's pipeline of investigational drugs and therapeutic products.
In addition to his role at Regeneron, Dr. Murphy is also recognized for his academic contributions. He holds a Ph.D. in a relevant scientific field and has been involved in numerous publications and presentations that outline advancements in genetic research and biotechnology. His leadership extends beyond his scientific acumen, as he plays a pivotal role in fostering collaborations with academic institutions, industry partners, and regulatory bodies to enhance the development and delivery of novel therapies.
Dr. Murphy's work continues to contribute significantly to Regeneron's mission of delivering innovative medicines to patients with unmet medical needs. His dedication to science and medicine exemplifies the impact of leadership in driving forward the boundaries of what is possible in biopharmaceutical research and development.
Mr. Daniel P. Van Plew is a prominent executive at Regeneron Pharmaceuticals, Inc., where he serves as the Executive Vice President and General Manager of Industrial Operations and Product Supply. As part of the leadership team, Van Plew plays a crucial role in overseeing the company's manufacturing and distribution operations. His responsibilities include managing Regeneron's large-scale manufacturing facilities, ensuring compliance with regulatory standards, and optimizing supply chain operations to meet global demand for the company's pharmaceutical products. With a strong background in biotechnology and pharmaceuticals, Van Plew joined Regeneron in 2007 and has since been instrumental in scaling up production capabilities, particularly in the context of biologics manufacturing. His leadership has contributed to Regeneron’s reputation for high-quality product supply, enabling the company to effectively respond to the healthcare needs worldwide. Prior to his tenure at Regeneron, Daniel P. Van Plew held positions in various biotechnology and healthcare companies, where he gained extensive experience in operations and management. His educational background and industry expertise have made him a key figure in advancing Regeneron’s operational excellence and maintaining its position as a leader in biopharmaceutical innovation.
With a strong background in biotechnology and pharmaceuticals, Van Plew joined Regeneron in 2007 and has since been instrumental in scaling up production capabilities, particularly in the context of biologics manufacturing. His leadership has contributed to Regeneron’s reputation for high-quality product supply, enabling the company to effectively respond to the healthcare needs worldwide.
Prior to his tenure at Regeneron, Daniel P. Van Plew held positions in various biotechnology and healthcare companies, where he gained extensive experience in operations and management. His educational background and industry expertise have made him a key figure in advancing Regeneron’s operational excellence and maintaining its position as a leader in biopharmaceutical innovation.
Christopher R. Fenimore is a notable executive at Regeneron Pharmaceuticals, Inc., where he currently serves as the Senior Vice President, Head of Accounting and Controller. As a Certified Public Accountant (CPA), he brings a wealth of expertise in financial management and accounting to the company. Fenimore oversees financial reporting, financial planning and analysis, operational finance, and internal controls, ensuring the company's financial integrity and compliance with accounting standards and regulations. His role is critical in supporting Regeneron's financial strategy, and he plays a significant part in helping the company navigate the complex regulatory environment of the pharmaceutical industry. His leadership and financial acumen contribute to Regeneron's ongoing success and expansion in developing innovative medicines. Fenimore's extensive experience in finance and accounting, complemented by his CPA credential, underscores his capability in managing the financial aspects of a major biotechnology firm effectively.
His role is critical in supporting Regeneron's financial strategy, and he plays a significant part in helping the company navigate the complex regulatory environment of the pharmaceutical industry. His leadership and financial acumen contribute to Regeneron's ongoing success and expansion in developing innovative medicines. Fenimore's extensive experience in finance and accounting, complemented by his CPA credential, underscores his capability in managing the financial aspects of a major biotechnology firm effectively.
Ryan Crowe is not publicly recognized or widely documented as an executive at Regeneron Pharmaceuticals Inc. There may be limited or no publicly available information about an individual by that name associated with the company. Please verify the spelling or provide additional context to assist further. If he is a less public figure or in a different role than commonly listed executives, detailed biographical information might not be readily accessible. If you're referring to another individual or require information about a different person at Regeneron, please provide additional details.
If you're referring to another individual or require information about a different person at Regeneron, please provide additional details.
Joseph J. LaRosa is a prominent legal professional known for his leadership and expertise in the pharmaceutical and biotechnology industries. At Regeneron Pharmaceuticals, Inc., he serves as the Executive Vice President, General Counsel, and Secretary. In his role, LaRosa is responsible for overseeing all legal matters pertaining to the company, including regulatory compliance, intellectual property, and corporate governance. Before joining Regeneron, LaRosa accumulated extensive experience in legal affairs, having worked with other major corporations in the healthcare sector. His distinguished career is marked by his ability to navigate complex legal environments and provide strategic counsel that supports the company's innovative efforts and business goals. LaRosa holds a Juris Doctor (J.D.) degree, underlining his profound knowledge and professional credentials in the field of law. His contributions at Regeneron are integral to the company's operations and its commitment to addressing unmet medical needs through innovative research and development.
Before joining Regeneron, LaRosa accumulated extensive experience in legal affairs, having worked with other major corporations in the healthcare sector. His distinguished career is marked by his ability to navigate complex legal environments and provide strategic counsel that supports the company's innovative efforts and business goals.
LaRosa holds a Juris Doctor (J.D.) degree, underlining his profound knowledge and professional credentials in the field of law. His contributions at Regeneron are integral to the company's operations and its commitment to addressing unmet medical needs through innovative research and development.
Melissa Lozner serves as the Executive Vice President, General Counsel, and Secretary at Regeneron Pharmaceuticals Inc. She joined Regeneron in 2019 as Vice President and Associate General Counsel, Regulatory & Litigation, and took on the role of General Counsel in 2022. At Regeneron, Lozner is responsible for overseeing all legal matters, leading the company's legal strategy, and ensuring regulatory compliance. Before her tenure at Regeneron, Lozner gained extensive legal experience at Bristol Myers Squibb, where she held various positions and worked on significant litigation and regulatory issues. Additionally, she previously served in roles at Skadden, Arps, Slate, Meagher & Flom LLP, a prestigious international law firm, where she specialized in litigation and regulatory matters. Lozner holds a J.D. from the University of Pennsylvania Law School and a B.A. from Georgetown University. Her combination of regulatory expertise and legal acumen makes her a significant contributor to Regeneron's leadership team.
Before her tenure at Regeneron, Lozner gained extensive legal experience at Bristol Myers Squibb, where she held various positions and worked on significant litigation and regulatory issues. Additionally, she previously served in roles at Skadden, Arps, Slate, Meagher & Flom LLP, a prestigious international law firm, where she specialized in litigation and regulatory matters.
Lozner holds a J.D. from the University of Pennsylvania Law School and a B.A. from Georgetown University. Her combination of regulatory expertise and legal acumen makes her a significant contributor to Regeneron's leadership team.
